Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Jul 1;102(1):130–135. doi: 10.1172/JCI2673

Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2.

P M Sullivan 1, H Mezdour 1, S H Quarfordt 1, N Maeda 1
PMCID: PMC509074  PMID: 9649566

Abstract

To study isoform-specific effects of apolipoprotein E (apoE) in vivo, we generated mice with a human APOE*2 allele in place of the mouse Apoe gene via targeted gene replacement in embryonic stem cells. Mice expressing human apoE2 (2/2) have virtually all the characteristics of type III hyperlipoproteinemia. Their plasma cholesterol and triglyceride levels are both twice to three times those in (normolipidemic) mice that are expressing human apoE3 (3/3) made in an identical manner. The 2/2 mice are markedly defective in clearing beta-migrating VLDL particles, and spontaneously develop atherosclerotic plaques, even on a regular diet. An atherogenic diet, high in fat and cholesterol, exacerbates development of atherosclerosis and xanthomas in the 2/2 mice. Thus, comparisons between the 2/2 and 3/3 mice unequivocally demonstrate that a single amino acid difference (Arg158 Cys) in the apoE protein is sufficient to cause type III HLP and spontaneous atherosclerosis in mice.

Full Text

The Full Text of this article is available as a PDF (322.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brewer H. B., Jr, Zech L. A., Gregg R. E., Schwartz D., Schaefer E. J. NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment. Ann Intern Med. 1983 May;98(5 Pt 1):623–640. doi: 10.7326/0003-4819-98-5-623. [DOI] [PubMed] [Google Scholar]
  2. Chappell D. A. Pre-beta-very low density lipoproteins as precursors of beta-very low density lipoproteins. A model for the pathogenesis of familial dysbetalipoproteinemia (type III hyperlipoproteinemia). J Clin Invest. 1988 Aug;82(2):628–639. doi: 10.1172/JCI113642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fazio S., Lee Y. L., Ji Z. S., Rall S. C., Jr Type III hyperlipoproteinemic phenotype in transgenic mice expressing dysfunctional apolipoprotein E. J Clin Invest. 1993 Sep;92(3):1497–1503. doi: 10.1172/JCI116728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fredrickson D. S., Levy R. I., Lees R. S. Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. N Engl J Med. 1967 Jan 5;276(1):34–contd. doi: 10.1056/NEJM196701052760107. [DOI] [PubMed] [Google Scholar]
  5. Goldstein J. L., Ho Y. K., Basu S. K., Brown M. S. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A. 1979 Jan;76(1):333–337. doi: 10.1073/pnas.76.1.333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Greeve J., Altkemper I., Dieterich J. H., Greten H., Windler E. Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. J Lipid Res. 1993 Aug;34(8):1367–1383. [PubMed] [Google Scholar]
  7. Hackler R., Schäfer J. R., Motzny S., Brand S., Kleine T. O., Kaffarnik H., Steinmetz A. Rapid determination of apolipoprotein E phenotypes from whole plasma by automated isoelectric focusing using PhastSystem and immunofixation. J Lipid Res. 1994 Jan;35(1):153–158. [PubMed] [Google Scholar]
  8. Hazzard W. R., Bierman E. L. Broad-beta disease versus endogenous hypertriglyceridemia: levels and lipid composition of chylomicrons and very low density lipoproteins during fat-free feeding and alimentary lipemia. Metabolism. 1975 Jul;24(7):817–828. doi: 10.1016/0026-0495(75)90128-6. [DOI] [PubMed] [Google Scholar]
  9. Henriksen T., Mahoney E. M., Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci U S A. 1981 Oct;78(10):6499–6503. doi: 10.1073/pnas.78.10.6499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Higuchi K., Kitagawa K., Kogishi K., Takeda T. Developmental and age-related changes in apolipoprotein B mRNA editing in mice. J Lipid Res. 1992 Dec;33(12):1753–1764. [PubMed] [Google Scholar]
  11. Hoogwerf B. J., Bantle J. P., Kuba K., Frantz I. D., Jr, Hunninghake D. B. Treatment of type III hyperlipoproteinemia with four different treatment regimens. Atherosclerosis. 1984 May-Jun;51(2-3):251–259. doi: 10.1016/0021-9150(84)90172-2. [DOI] [PubMed] [Google Scholar]
  12. Huang Y., Rall S. C., Jr, Mahley R. W. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2817–2824. doi: 10.1161/01.atv.17.11.2817. [DOI] [PubMed] [Google Scholar]
  13. Huang Y., Schwendner S. W., Rall S. C., Jr, Mahley R. W. Hypolipidemic and hyperlipidemic phenotypes in transgenic mice expressing human apolipoprotein E2. J Biol Chem. 1996 Nov 15;271(46):29146–29151. doi: 10.1074/jbc.271.46.29146. [DOI] [PubMed] [Google Scholar]
  14. Huang Y., Schwendner S. W., Rall S. C., Jr, Sanan D. A., Mahley R. W. Apolipoprotein E2 transgenic rabbits. Modulation of the type III hyperlipoproteinemic phenotype by estrogen and occurrence of spontaneous atherosclerosis. J Biol Chem. 1997 Sep 5;272(36):22685–22694. doi: 10.1074/jbc.272.36.22685. [DOI] [PubMed] [Google Scholar]
  15. Nishina P. M., Verstuyft J., Paigen B. Synthetic low and high fat diets for the study of atherosclerosis in the mouse. J Lipid Res. 1990 May;31(5):859–869. [PubMed] [Google Scholar]
  16. Parker F. Xanthomas and hyperlipidemias. J Am Acad Dermatol. 1985 Jul;13(1):1–30. doi: 10.1016/s0190-9622(85)70139-9. [DOI] [PubMed] [Google Scholar]
  17. Plump A. S., Smith J. D., Hayek T., Aalto-Setälä K., Walsh A., Verstuyft J. G., Rubin E. M., Breslow J. L. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992 Oct 16;71(2):343–353. doi: 10.1016/0092-8674(92)90362-g. [DOI] [PubMed] [Google Scholar]
  18. Polano M. K. Xanthomatosis and hyperlipoproteinemia; a review. Dermatologica. 1974;149(1):1–9. [PubMed] [Google Scholar]
  19. Quarfordt S. H., Oswald B., Landis B., Xu H. S., Zhang S. H., Maeda N. In vivo cholesterol kinetics in apolipoprotein E-deficient and control mice. J Lipid Res. 1995 Jun;36(6):1227–1235. [PubMed] [Google Scholar]
  20. Schaefer E. J., Levy R. I. Pathogenesis and management of lipoprotein disorders. N Engl J Med. 1985 May 16;312(20):1300–1310. doi: 10.1056/NEJM198505163122007. [DOI] [PubMed] [Google Scholar]
  21. Sullivan P. M., Mezdour H., Aratani Y., Knouff C., Najib J., Reddick R. L., Quarfordt S. H., Maeda N. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem. 1997 Jul 18;272(29):17972–17980. doi: 10.1074/jbc.272.29.17972. [DOI] [PubMed] [Google Scholar]
  22. Utermann G., Hees M., Steinmetz A. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature. 1977 Oct 13;269(5629):604–607. doi: 10.1038/269604a0. [DOI] [PubMed] [Google Scholar]
  23. Weisgraber K. H., Innerarity T. L., Mahley R. W. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem. 1982 Mar 10;257(5):2518–2521. [PubMed] [Google Scholar]
  24. Zhang S. H., Reddick R. L., Burkey B., Maeda N. Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. J Clin Invest. 1994 Sep;94(3):937–945. doi: 10.1172/JCI117460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Zhang S. H., Reddick R. L., Piedrahita J. A., Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992 Oct 16;258(5081):468–471. doi: 10.1126/science.1411543. [DOI] [PubMed] [Google Scholar]
  26. van Vlijmen B. J., van Dijk K. W., van't Hof H. B., van Gorp P. J., van der Zee A., van der Boom H., Breuer M. L., Hofker M. H., Havekes L. M. In the absence of endogenous mouse apolipoprotein E, apolipoprotein E*2(Arg-158 --> Cys) transgenic mice develop more severe hyperlipoproteinemia than apolipoprotein E*3-Leiden transgenic mice. J Biol Chem. 1996 Nov 29;271(48):30595–30602. doi: 10.1074/jbc.271.48.30595. [DOI] [PubMed] [Google Scholar]
  27. van den Maagdenberg A. M., Hofker M. H., Krimpenfort P. J., de Bruijn I., van Vlijmen B., van der Boom H., Havekes L. M., Frants R. R. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem. 1993 May 15;268(14):10540–10545. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES